Side-by-side · Research reference
ARA 290vsGonadorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BFDA-ApprovedHUMAN-REVIEWED7/61 cited
Gonadorelin
GnRH Analogue · Diagnostic & Therapeutic
IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)
01Mechanism of Action
Parameter
ARA 290
Gonadorelin
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
GnRH receptors on anterior pituitary gonadotropes
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026Sharma 2026
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
Gonadorelin
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
Continuous until pregnancy achieved or fertility goals met
3–6 month courses typical for ovulation induction.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
RCT / Expert consensus
Timing
Any time of day
No circadian dependence reported.
—
Diagnostic test (pituitary function)
—
100 mcg IV or SQ bolus
Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.
Therapeutic (hypothalamic hypogonadism)
—
5–20 mcg IV bolus every 90–120 minutes
Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026
Pulsatile interval
—
90 minutes (females) · 120 minutes (males)
Mimics physiological GnRH pulse frequency.
Half-life
—
2–4 minutes (plasma)
Necessitates frequent pulsatile administration.
Alternative protocols
—
Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Gonadorelin
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
Fat loss mechanism
—
None — gonadorelin acts exclusively on reproductive axis
Indirect metabolic effects
—
Restoration of sex hormones may normalize body composition in hypogonadal states
Effect mediated by downstream testosterone/estradiol, not GnRH itself.
04Side Effects & Safety
Parameter
ARA 290
Gonadorelin
Injection site reaction
Mild, transient
Erythema, irritation (pulsatile pump catheter site)
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Headache
—
Common with bolus administration
Nausea / abdominal discomfort
—
Transient, dose-related
Ovarian hyperstimulation syndrome (OHSS)
—
Risk with ovulation induction protocols; monitor follicular development via ultrasound
Multiple gestation
—
Increased risk with fertility protocols (twins ~10–15%)
Anaphylaxis
—
Rare hypersensitivity reaction
Pump malfunction / infection
—
Mechanical failure or catheter-site infection with long-term IV pump use
Receptor desensitization
—
Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Gonadorelin
- ·Pregnancy (except therapeutic infertility protocols)
- ·Hypersensitivity to gonadorelin or excipients
- ·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Gonadorelin
- ·Ovarian cysts or PCOS (monitor for OHSS)
- ·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)
05Administration Protocol
Parameter
ARA 290
Gonadorelin
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Gonadorelin
+ hCG (Human Chorionic Gonadotropin)
Multi-pathwayIn hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.
- Gonadorelin
- 5–10 mcg IV every 120 min (pulsatile pump)
- hCG
- 1500–2000 IU SQ · 2–3× per week
- Duration
- 12–24 weeks for spermatogenesis induction
- Primary benefit
- Fertility restoration in hypothalamic hypogonadism with maintained testicular function